Saturna Capital Corp Denali Therapeutics Inc. Transaction History
Saturna Capital Corp
- $7.5 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding DNLI
# of Institutions
227Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$279 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$276 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$234 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$224 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$165 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.81B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...